|
28 Apr 2019 |
Genexine and NeoImmuneTech Announce Dosing of First Patient in the Combination Trial of Hyleukin-7™ with Merck’s KEYTRUDA® in Triple-Negative Breast Cancer
|
|
28 Apr 2019 |
Alexion Receives Positive CHMP Opinion for ULTOMIRIS® (ravulizumab) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
|
26 Apr 2019 |
Merck Provides Update on Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
|
|
24 Apr 2019 |
GT Biopharma (GTBP) Announces the Elimination of HIV Infected Cells Using its Tri-Specific Killer Engagers (TriKEs) in Preclinical Testing at the University of Minnesota
|
|
24 Apr 2019 |
Innovent Announces First Patient Dosed in Phase I Clinical Trial of IBI318 Bispecific Antibody in China
|
|
24 Apr 2019 |
Teva Announces Update on Fremanezumab Clinical Development for use in Episodic Cluster Headache
|
|
24 Apr 2019 |
AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI™ (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis
|
|
24 Apr 2019 |
Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
|
|
23 Apr 2019 |
Molecular Templates Announces FDA Acceptance of IND Application for MT-5111, An Engineered Toxin Body Targeting HER2
|
|
23 Apr 2019 |
U.S. Food and Drug Administration Accepts Biologics License Application for Eptinezumab
|
|
23 Apr 2019 |
Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
|
|
22 Apr 2019 |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)
|
|
19 Apr 2019 |
TAU BIO-LOGIC Announces Humanization of Picomolar Affinity Monoclonal Antibody Targeting TauC3 Protein for the Treatment of Alzheimer's Disease and Progressive Supranuclear Palsy
|
|
19 Apr 2019 |
Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis
|
|
19 Apr 2019 |
Nemolizumab Achieves Primary Endpoint in Phase 3 Clinical Study (Comparative Study) in Japan for the Treatment of Atopic Dermatitis
|
|
19 Apr 2019 |
Prothena Reports Results from the Phase 3 VITAL Amyloidosis Study of NEOD001 (birtamimab) in AL Amyloidosis
|
|
18 Apr 2019 |
Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T cell Engager (HPN536) in Phase 1/2a Clinical Trial for Ovarian and Other Solid Tumor Cancers
|
|
18 Apr 2019 |
Innovent Announces First Patient Dosed in a Phase I Clinical Trial of IBI302 for the Treatment of Wet AMD
|
|
18 Apr 2019 |
Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder
|
|
16 Apr 2019 |
Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
|
|
16 Apr 2019 |
Eureka Therapeutics Announces Publication of Preclinical Study Demonstrating Selective Depletion of Tregs Using Foxp3 Targeting TCR-mimic Antibody
|
|
15 Apr 2019 |
Zymeworks Opens Phase 2 Clinical Trial for ZW25 in First-Line HER2-Expressing Metastatic Gastroesophageal Cancers
|
|
13 Apr 2019 |
TRACON Pharmaceuticals Announces Termination of Phase 3 TAPPAS Trial Based on the Recommendation of the Independent Data Monitoring Committee
|
|
12 Apr 2019 |
Trogarzo® Receives Positive Recommendation from Scientific Advisory Group of CHMP in Europe
|
|
12 Apr 2019 |
FDA Approves Expanded Monotherapy Label for Merck’s KEYTRUDA® (pembrolizumab)
|
